of the signal but also as so-called oncogenes. In the light of
most important pathways for cell proliferation, the MAPK pathway. Here we show the constitutive activation of this pathway in a comparatively large proportion of patients with Introduction acute leukemia.
Mitogen-activated protein kinases (MAPKs), also known as extracellular signal-regulated kinases (ERKs), [1] [2] [3] [4] [5] are serine/ Materials and methods threonine kinases that appear to convert a variety of extracellular signals such as growth factors and cytokines to cell Leukemia cells growth or differentiation. MAPKs translocate to the nucleus upon activation [6] [7] [8] and a number of transcription factors We used 40 fresh heparinized leukemia samples which were including c-jun, 9 Elk-1, 10 c-myc, 11 and NF-IL6 12 have been separated by Ficoll-Hypaque, washed twice with phosphaterevealed to be phosphorylated and activated by MAPKs. buffered saline (PBS) followed by the extraction of whole cell MAPKs are therefore key kinases in the intracellular signal lysates. The other 60 samples, previously frozen by a contransduction pathways.
trolled-rate freezer to −80°C and stocked in liquid nitrogen, A large number of leukemia-specific cytogenetic abnormaliwere subjected to quick thawing and extraction of whole cell ties have been identified and the genes involved cloned. 13, 14 lysate. The viability was assessed by the trypan blue exclusion Some of them, including receptor abnormalities, appear to test. All acute leukemia samples contained over 90% viable involve the signal transduction pathways, which have drawn blast cells. Hematological malignancies analyzed included 73 attention as another possible mechanism for leukemogenesis; acute myelogenous leukemias (AMLs) (five M0, 16 M1, 20 one such pathway is the receptor tyrosine kinase-mediated M2, 10 M3, 11 M4, 10 M5 and one M6 in the French-Amerpathway. Mutations of c-fms, 15 M-CSF receptor, or c-kit recepican-British classification), 13 acute lymphoblastic leukemias tor tyrosine kinase 16 have been revealed to activate hemato-(ALLs) (four T-ALL and nine B-lineage ALL), and 14 chronic poietic cell proliferation. A frameshift mutation in the erythromyelogenous leukemias (CML) (six chronic phase and four poietin receptor was reported in primary familial myeloid/four lymphoid blastic crisis). Whole cell lysates were polycythemia. 17 Continuous activation of these cytokine extracted as reported previously. 25 Concisely, the cells were receptors activates the shared signal transduction pathways lysed in RIPA buffer (10 mM Tris-HCl, pH 7.5, 0.4 M NaCl, 1% resulting in the constitutive activation of the downstream Nonidet P-40, 0.1% sodium deoxycholate, 0.1% sodium laucomponents. The upstream components of MAPK pathway ryl sulfate (SDS), 1 mM EDTA) containing 20 g/ml aprotinin, contain the GTP-binding protein p21Ras which binds to the 20 g/ml leupeptin, 1mM benzamidine, 1 mM phenylmethylsulfonyl fluoride (PMSF), 3 mM sodium vanadate and 40 mM sodium pyrophosphate. The activity in each sample was measured by the relative intensity of each band estimated by a phosphoimage The SDS polyacrylamide gel for resolving the mobility shift between the phosphorylated form and unphosphorylated form analyzer (BAS2000, FUJIX, Tokyo, Japan). The relative ratio of the intensity of the phosphorylated form to the total intensity of MAPK contained low bisacrylamide as we described previously.
19,25 The bands were detected by either polyclonal of the phosphorylated and unphosphorylated forms was calculated; samples with more than 5% phosphorylation were arbianti-ERK2 antibody or anti-ERK1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) which is not crosstrarily defined as positive, because a large portion of the sample with visible phosphorylated band showed a much higher reactive with ERK1 p44 or ERK2 p42, respectively, followed by ECL kit (Amersham International, Buckinghamshire, UK).
number, while the negative sample always showed a much smaller one. Normal bone marrow samples invariably exhibited less than 1% ERK2 phosphorylation. Representative data were shown in Figure 1a . In 18 of 40 freshly extracted samples MAPK activity assay and 22 of 60 frozen-thawed samples, the phosphorylated form of MAPK was enhanced by more than 5%. A summary of the Activity of MAPK was assessed by the kinase activity for the synthesized peptide using a commercial kit (BIOTRAK MAP results were presented in Table 1 . In AMLs, all subtypes of the FAB classification, except M0 and M6, contained a relatively kinase assay; Amersham). The peptide contains the sequence PLS/TP, a recognition sequence for p42/p44 MAPK, 26 and no high percentage of the positive samples: 37 out of 73 samples were positive in AMLs in total (average of phosphorylated other phosphorylation sites. Therefore, this assay reflects the MAPK activity more specifically than a standard MBP phosform ratio, 22%). Three of nine B-lineage ALL and none of three CLL had positive phosphorylation of MAPK. Interestphorylation assay.
ingly, neither the chronic phase nor the acute (blastic) phase of CML showed any detectable phosphorylated form of ERK2. The marrow cells in complete remission showed minimal
Kinase activity for GST-ERK2
ERK2 phosphorylation even at the recovery phase after consolidation chemotherapy (Figure 1a , lanes 7 and 13). PhosFull-length human ERK2 cDNA was cloned into the pGEX-2T vector (Pharmacia Biotechnology, Uppsala, Sweden) and phorylation of ERK1, an isoform of ERK2, was also examined in 20 leukemia samples by the same gel shift assay, and the GST-ERK2 was generated bacterially as recommended by the manufacturer (Pharmacia). The reaction mixture contained representative data are shown in Figure 1b . All 10 ERK2-phosphorylated samples exhibited enhanced phosphorylation 10 g of glutathione-S-transferase (GST)-ERK2 coupled with glutathione agarose, 1 g of whole cell lysate, 10 mM HEPES (average of phosphorylated form ratio, 17%), while the other (pH 7.6), 10 mM MgCl 2 , 1 mM DTT, and 370 kBq of ␥ 32 P-ATP. The reaction was censored after incubation at 30°C for The regions centering on codon 12 of K-ras and N-ras, and using PCR. Ras mutations were detected by an algorithm
based on allele-specific oligonucleotide hybridization. The We first examined activation of MAPK (ERK2) in leukemia Total 100 40 40 cells by immunoblotting. Equal amounts of whole cell lysates were subjected to SDS-PAGE followed by immunoblotting a Percent intensity of phosphorylated ERK2 vs total intensity of phoswith polyclonal antibody against ERK2 and then transferred to phorylated and unphosphorylated ERK2 was calculated. Samples the PVDF membrane. The quality and quantity of each lysate with more than 5% phosphorylation were defined as positive.
were confirmed by SDS-PAGE followed by Coomassie blue b Chronic phase.
staining. We found that the freezing-thawing procedure con- Table 2 , respectively; lanes 5 and 6, normal bone marrow cells; lanes 7 and 13, CR bone marrow cells at recovery phase from the same patients of lanes 8 and 12 (at initial diagnosis), respectively. (b) Close correlation of phosphorylation of ERK1 with ERK2 phosphorylation. Each number of the lanes corresponds to the same number of lanes in Figure 1a, respectively. Similar to ERK2, the slower migrating band (band a) and faster migrating band (band b) represent phosphorylated and unphosphorylated forms of ERK1, respectively. 10 samples with minimal ERK2 phosphorylation all exhibited less than 5% ERK1 phosphorylation. We may therefore conclude that ERK2 phosphorylation (activation) is frequently accompanied with ERK1 phosphorylation (activation) in these acute leukemia cells, although the unique or cooperative function of these isoforms is unknown. To confirm whether the activity of MAPK is proportional to the phosphorylation status, we assayed the kinase activity by a commercial kit with a very specific substrate (synthesized peptide) for ERK1 and ERK2. Representative data are shown in Figure 2 . While normal bone marrow and other leukemia samples simply showed background levels, the leukemia samples with the positive mobility shifts (lanes 8-12) showed over 10-to 40-fold higher MAPK activity, suggesting that MAPK in these leukemia cells is indeed activated. tein indicates the MAPKK (MEK1/MEK2) activity in the lysates.
Activation of MAPKK and mutations of N-ras gene
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As shown in Figure 3a , the samples which possessed constitutactivated by point mutations such as c-fms 15 or c-kit. 16 Another candidate is Ras oncogene which lies upstream of ively elevated MAPK activity also showed elevated MAPKK activity (lanes 4-7) , whereas the leukemia samples with basal Raf-MAPKK-MAPK. We found that two AML samples out of 10 ERK2-positive leukemia samples had N-ras mutations in MAPK activity did not reveal any activated MAPKK by this assay. None of these lysates (sample Nos 9-12 in Table 2) the hot spots (Table 2) . Although mutations were infrequently observed except the hot spots, Ras mutations seem not to be showed phosphorylation of GST alone when we replaced GST-ERK2 protein with GST protein (data not shown). The the exclusive cause of the constitutive activation in 40% of acute leukemia cases. It is of interest to see whether all AML integrity and amount of incubated GST-ERK2 were visualized by Coomassie blue staining of the gels (Figure 3b) , showing samples with functional Ras mutations actually show the constitutive active MAPK. Very recently, isoforms of MAPKK no significant alteration of the applied amount of GST-ERK2.
We next examined the possible mutations of Ras gene, were cloned and demonstrated to define independent MAPK signal transduction pathways. 40 Among this expanding numwhich is the upstream component of the MAPK pathway and sometimes found to have mutations in small portions of AMLs ber of components, it should be clarified which components, including Ras genes, are responsible for the constitutive actiand acute phase of CML; codons 12, 13 and 61 are the hot spots in the Ras (especially N-and K-ras) gene mutations.
vation of MAPKs in acute leukemia. It is also of importance to determine a possible correlation They have variously been reported to account for approximately 20% of all AMLs at most and much less in CML or between the activation of MAPK and clinical features. It might be interesting to find most CML cells do not show any signifi-ALL. [21] [22] [23] [24] In our experiments, two of 10 ERK2-positive samples had N-ras gene mutation at codon 12 ( Table 2 ). Although this cantly high MAPK activity; none of six samples at chronic phase and none of eight at blastic crisis showed constitutive experiment was performed with limited numbers of samples, it seems that all ERK-2 positive samples do not have abnormal activation of MAPK. In contrast, the AML samples with positive MAPK activity encompass various subclasses of FAB Ras genes.
classification (from M1 to M5). It seems noteworthy that high incidence of ERK2 activation in M2 and M5 leukemias was observed, with a lower frequency of activation in other subDiscussion classes (P Ͻ 0.05). Very recently, activation of the MAPK pathway in human renal cell carcinoma with 48% positivity of The present study demonstrated a high frequency of constitutive activation of MAPK (ERK2) in human primary acute leukeactivated MAPK was found to be closely associated with the disease stages. 41 In leukemias, however, it is difficult to estimia cells. The marrow cells at the recovery phase after chemotherapy as well as the normal bone marrow cells revealed mate the exact stage of malignancy. A prospective large scale study with multivariate analysis is needed to clarify this issue. minimal MAPK and MAPKK activity, suggesting that activation of MAPK (ERK2) in normal bone marrow tissues is below Finally, it is of great interest to elucidate the exact role of MAPK when it is constitutively activated in a variety of heterodetectable levels. In contrast, 40% of the leukemia cells examined had a clear elevation of MAPK activity at initial diagnosis.
genous hematological malignancies. The duration of the MAPK pathway activation can be a crucial factor in determinTumorigenesis in humans appears to be a multistep process. 31 Although we showed evidence that constitutive activation of ing cell fate. In the PC12 chromaffin cell line, constitutive activation of MAPK by mutant MAPKK leads to differentiation, MAPK in AML occurs very frequently, the mechanism of MAPK activation may be heterogenous. Many different causes while its transient activation induces proliferation. 1 Conversely, in fibroblasts, sustained activation of MAPKs is assocould trigger MAPK activation. A number of hematopoietic growth factors (HGFs) such as IL-3, GM-CSF, SF, and IL-6 ciated with proliferation, but not differentiation. 19, 20, 42 These findings lend support to the idea that the cellular response is stimulate MAPK pathway. 32, 33 In experimental models, autocrine growth factor stimulation, which may activate the determined by which transcription factors are present in the cell. It is fascinating to speculate that constitutively activated signal transduction pathway constitutively, can be a critical step in leukemogenesis. [34] [35] [36] [37] [38] [39] We should also bear in mind that MAPKs may specifically phosphorylate and transactivate the transcription factors and that they may then regulate the tyrosine kinase, including receptor tyrosine kinases, might be
Figure 3
Activity to phosphorylate GST-ERK2. (a) After incubation of an equivalent amount of GST-ERK2 with each lysate, GST-ERK2 protein was precipitated with glutathione agarose, washed five times, boiled in the sample buffer, and applied to SDS-PAGE. The gels were then subjected to phosphoimage analyzer to estimate the phosphorylation activity for GST-ERK2. The representative data are shown. Lane 1, no lysate; lanes 2 and 3, sample Nos 2 and 3; lanes 4-7, sample Nos 9-12 in Table 2 , respectively. (b) The integrity and amount of GST-ERK2 applied were visualized by staining the same gel of Figure 3a with Brilliant Coomassie blue. 
